CHEMED CORP

Chemed Corp’s CEO sells 2,000 shares—what this quiet move says about the company’s outlook and future growth potential.

Chemed Corp insiders reveal a strategic shift: CEO McNamara buys low and sells high, signalling confidence in long‑term value and growth prospects.

Andrea LinDell’s June 9 insider sale of CHEMED shares—amid minimal price change but high social‑media buzz—raises questions about insider liquidity and future investor confidence.

Insider buying spikes Chemed Corp’s optimism—leaders buy 386 shares each as the company keeps a strong dividend track record, hinting at future upside and income‑seeking value.

Chemed insider sale: Grace Patrick’s 60‑share trade shows conservative liquidity use amid CEO liquidations—investors weigh confidence vs. short‑term cash needs.

CEO Kevin McNamara’s 2,000‑share sale at $403.18 signals strategic liquidity and possible future growth plans for Chemed Corp., alerting investors to potential short‑term volatility and long‑term upside.

Chemed Corp’s VP Thomas Hutton buys 199 shares amid a $300 m buy‑back and steady $0.60 dividend, signaling insider confidence and potential upside for investors.

Insider buying by Chemed Corp CEO Wherley Joel L signals confidence after performance‑based vesting, backed by a $300M buyback and steady dividends, hinting at potential upside for investors.

Chemed Corp’s CFO’s recent PSU trades and buybacks signal confidence in growth, blending liquidity needs with long‑term commitment to shareholders.

Chemed’s CEO buys shares amid a $300 M share‑repurchase and $0.60 dividend, signaling confidence in undervalued stock and a potential entry point for value investors.